Literature DB >> 10421602

Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors.

S Rohrbach1, X Yan, E O Weinberg, F Hasan, J Bartunek, M A Marchionni, B H Lorell.   

Abstract

BACKGROUND: Neuregulins are a family of peptide growth factors that promote cell growth and viability. The potential role of neuregulin-erbB signaling in hypertrophic growth and later failure in the adult heart in vivo is not known. METHODS AND
RESULTS: We used ribonuclease protection assays to quantify mRNA levels of neuregulin, erbB2, and erbB4 in left ventricular (LV) tissue and myocytes of normal rats and rats with aortic stenosis with pressure-overload hypertrophy 6 and 22 weeks after banding. At both stages of hypertrophy, Northern blot analyses of mRNA from LV myocytes showed upregulation of atrial natriuretic peptide, a molecular marker of hypertrophy (P<0.05). LV tissue neuregulin message levels were similar in animals with aortic stenosis compared with controls (P=NS) and were not detectable in myocytes. LV erbB2 and erbB4 message levels in LV tissue and myocytes were maintained during early compensatory hypertrophy in 6-week aortic stenosis animals compared with age-matched controls; in contrast, erbB2 and erbB4 message levels were depressed in 22-week aortic stenosis animals at the stage of early failure (both P<0.01 vs age-matched controls). Immunoblotting of erbB2 and erbB4 also showed normal protein levels in 6-week aortic stenosis animals compared with controls; however, erbB2 and erbB4 protein levels were depressed in 22-week aortic stenosis animals (48% decrease in erbB2, P<0.05, and 43% decrease in erbB4, P<0.01) relative to age-matched controls.
CONCLUSIONS: The neuregulin receptors erbB2 and erbB4 are downregulated at both the message and protein levels at the stage of early failure in animals with chronic hypertrophy secondary to aortic stenosis. These data suggest a role for disabled erbB receptor signaling in the transition from compensatory hypertrophy to failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421602     DOI: 10.1161/01.cir.100.4.407

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

Review 2.  The role of Neuregulin-1beta/ErbB signaling in the heart.

Authors:  Laura Pentassuglia; Douglas B Sawyer
Journal:  Exp Cell Res       Date:  2008-09-03       Impact factor: 3.905

Review 3.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

4.  Adaptive regulation of riboflavin transport in heart: effect of dietary riboflavin deficiency in cardiovascular pathogenesis.

Authors:  Tamilarasan Udhayabanu; Sellamuthu Karthi; Ayyavu Mahesh; Perumal Varalakshmi; Andreea Manole; Henry Houlden; Balasubramaniem Ashokkumar
Journal:  Mol Cell Biochem       Date:  2017-08-23       Impact factor: 3.396

5.  Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.

Authors:  Polina Sysa-Shah; Carlo G Tocchetti; Manveen Gupta; Peter P Rainer; Xiaoxu Shen; Byung-Hak Kang; Frances Belmonte; Jian Li; Yi Xu; Xin Guo; Djahida Bedja; Wei Dong Gao; Nazareno Paolocci; Rutwik Rath; Douglas B Sawyer; Sathyamangla V Naga Prasad; Kathleen Gabrielson
Journal:  Cardiovasc Res       Date:  2015-12-21       Impact factor: 10.787

6.  Palmitate alters neuregulin signaling and biology in cardiac myocytes.

Authors:  Thomas A Miller; Basak Icli; Gregory M Cote; Nathan K Lebrasseur; Steve C Borkan; David R Pimentel; Xuyang Peng; Douglas B Sawyer
Journal:  Biochem Biophys Res Commun       Date:  2008-12-12       Impact factor: 3.575

Review 7.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

Review 8.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

9.  Neuregulin protects human umbilical vein endothelial cell via activating CD98hc through MAPK pathway.

Authors:  Shenghu He; Jing Zhang; Xiang Qi; Daxin Wang; Xuefei Wang; Shenghua Zhou
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.

Authors:  Cemil Ozcelik; Bettina Erdmann; Bernhard Pilz; Nina Wettschureck; Stefan Britsch; Norbert Hübner; Kenneth R Chien; Carmen Birchmeier; Alistair N Garratt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.